Japanese Personal Products Stock News

In early March 2026, Kyowa Kirin Co., Ltd. announced it would discontinue all clinical trials of rocatinlimab, an investigational anti-OX40 antibody for moderate-to-severe atopic dermatitis, prurigo nodularis, and asthma, following a planned safety review conducted with partner Amgen. The decision was driven by emerging malignancy signals, including confirmed and suspected cases of Kaposi’s sarcoma that, despite low overall incidence, raised plausible mechanistic concerns about OX40 pathway...

Resona Holdings, Inc. recently approved changes to its top leadership, appointing long-time insider Shinichiro Isa as Deputy President, Representative Executive Officer, Group CFO and Group CDO, and elevating Nobuki Iwadate to Group Chief Human Resources Officer, Deputy President and Representative Executive Officer, effective April 1, 2026. The concentration of financial, digital and human capital oversight in the hands of two experienced internal leaders may meaningfully influence how...

A UK parliamentary committee has increased pressure on Fujitsu (TSE:6702), criticising its lack of financial contribution to the nearly £1.5b Post Office Horizon redress bill and questioning its ongoing role in public contracts. See our latest analysis for Fujitsu. For context, Fujitsu’s share price return has been weak in the short term, with a 10.33% 1 month and 17.03% year to date decline. However, its 1 year total shareholder return of 21.30% and 3 year total shareholder return above 100%...

Sompo Holdings (TSE:8630) has put governance and trust at the center of its story, updating regulators on reforms around fraudulent auto claims, premium practices, and data leaks that previously challenged its reputation. See our latest analysis for Sompo Holdings. Alongside these governance updates and the Aspen integration in the UK, Sompo Holdings’ ¥5,829 share price comes after a 90 day share price return of 12.10% and a 1 year total shareholder return of 32.92%. The 3 year total...

In March 2026, Meiji America Inc. announced a US$65,000,000 investment to add Hello Panda production and upgrade equipment at its York, Pennsylvania facility, aiming to lift manufacturing capacity by 50% and support new jobs and local partnerships. Bringing Hello Panda production onshore to York could tighten Meiji’s North American supply chain and deepen collaboration with major U.S. retailers. We’ll now consider how this new Hello Panda capacity in York may influence Meiji Holdings’...

Why Aichi Financial Group Stock Is Back in Focus After Its Governance Shakeup Aichi Financial Group (TSE:7389) has moved into the spotlight after its board approved a broad reorganization of compliance, risk, sales, and markets functions, alongside significant board and executive lineup changes. These shifts, which start from April 2026 and run through June 2026, are designed to tighten integration between Aichi Financial Group, Aichi Bank, and the group leasing subsidiary while reshaping...

Why SBI Holdings (TSE:8473) just moved its dividend goalposts SBI Holdings (TSE:8473) has raised its year end dividend forecast to ¥75 per share and highlighted a completed ¥50b share buyback, following a board decision tied to profits in its Financial Services Business. See our latest analysis for SBI Holdings. The updated dividend and completed ¥50b buyback come after a weaker run in the share price, with a 30 day share price return of 17.6% and a year to date return of 14.26%. This...

Kyoto Financial Group Inc (TSE:5844) has drawn investor attention after sharply raising its earnings guidance, funded by large gains on equity sales, and pairing that move with a special dividend and expanded share buyback plan. See our latest analysis for Kyoto Financial GroupInc. The flurry of guidance upgrades, special dividend plans and the expanded buyback has coincided with strong recent momentum, with a 30 day share price return of 15.21% and a 1 year total shareholder return of...

Governance dispute focuses attention on Kobayashi Pharmaceutical Oasis Management’s public campaign against Kobayashi Pharmaceutical (TSE:4967) and its move to a Company with an Audit and Supervisory Committee has pushed the company’s governance structure and board oversight firmly into the spotlight for shareholders. See our latest analysis for Kobayashi Pharmaceutical. The governance dispute has arrived after a period where the 90 day share price return of 7.41% contrasts with a weaker 3...

Why IHI (TSE:7013) is on investors’ radar today IHI (TSE:7013) has recently drawn attention after a period of mixed share performance, with a negative month but a strong past 3 months and 1 year total return. This has prompted fresh questions about how its current valuation lines up with fundamentals. See our latest analysis for IHI. At a share price of ¥3,734.0, IHI has recently seen a 10.02% 1 month share price decline, following a strong 27.42% 3 month share price return and a very large 5...

Internet Initiative Japan (TSE:3774) has introduced a new Internal Vulnerability Assessment service within its Safous Security Assessment offering, giving customers broader visibility into security risks across internal networks and distributed sites. See our latest analysis for Internet Initiative Japan. The new security service arrives as Internet Initiative Japan’s share price trades at ¥2,333.5, with a 7 day share price return of 3.55% and a 30 day share price return of 4.97%. This...

Mitsubishi UFJ Financial Group (TSE:8306) has announced significant leadership changes at the senior executive level. Takuya Tanaka has been appointed Senior Managing Corporate Executive with responsibilities linked to commercial banking and wealth management. Yoshiaki Ueno has been appointed Managing Corporate Executive with a focus on corporate planning and group level management. These appointments mark a reshuffling of top roles that could influence group wide priorities and capital...

J.S.B.Co.Ltd (TSE:3480) opened Q1 2026 with revenue of ¥16.8b and basic EPS of ¥18.13, alongside trailing twelve month EPS of ¥285.67 on revenue of ¥77.6b. Over recent quarters the company has seen quarterly revenue move between ¥15.3b and ¥27.0b while basic EPS has ranged from a loss of ¥24.20 per share to a profit of ¥267.87 per share, giving investors a wide set of earnings outcomes to weigh against the current print. With trailing net profit margin at 7.8% compared with 7.3% a year...

Pharma Foods International (TSE:2929) has just posted its Q2 2026 numbers, with revenue of ¥16.7 billion and basic EPS of ¥2.31, alongside net income of ¥67 million. Over the last six quarters, the company has seen quarterly revenue move between ¥14.6 billion and ¥18.4 billion. Basic EPS has swung from a loss of ¥65.50 to a gain of ¥51.59 before landing at the latest ¥2.31 print, which puts the spotlight firmly on how much of that top line is actually flowing through to shareholders. For...

Eternal Hospitality GroupLtd (TSE:3193) has posted its Q2 2026 numbers with revenue of ¥12.8 billion and basic EPS of ¥25.03, alongside net income of ¥288.78 million, giving investors a clear snapshot of mid year trading. The company has seen quarterly revenue move from ¥11.2 billion in Q2 2025 to ¥12.8 billion in Q2 2026, while basic EPS shifted from ¥28.28 to ¥25.03 over the same period, and investors will be weighing these trends against the latest margin picture and how efficiently those...

Maruzen CHI HoldingsLtd (TSE:3159) has wrapped up FY 2026 with fourth quarter revenue of ¥43.3b and basic EPS of ¥2.47, rounding out a year where quarterly revenue ranged between ¥43.1b and ¥49.3b and EPS moved from ¥17.29 in Q1 to ¥2.47 in Q4. Across the latest trailing twelve months, revenue came in at ¥185.1b with basic EPS of ¥36.03, which may encourage investors to focus less on headline growth stories and more on how the business is converting that top line into earnings. With trailing...

Kumiai Chemical Industry (TSE:4996) has opened fiscal 2026 with Q1 revenue of ¥46,707 million and basic EPS of ¥32.74, setting a fresh reference point after a volatile run of quarterly earnings. The company has seen revenue move from ¥43,381 million in Q1 2025 to ¥46,707 million in Q1 2026, while basic EPS shifted from ¥33.25 to ¥32.74 over the same periods. This gives investors a clean snapshot of the top and bottom line as they weigh how a thinner 2.5% trailing net margin and that prior...

GIGABYTE recently announced a collaboration with Capcom to promote the upcoming Resident Evil Requiem game through a themed custom PC giveaway and bundled monitor-game offers, while Capcom’s board approved director changes and new management roles effective April 1, 2026. Together, the gaming hardware tie-in and leadership reshuffle highlight how Capcom is leaning on flagship IP while refining its internal business focus. We’ll now examine how the Resident Evil Requiem collaboration with...

Wondering whether SoftBank Group's current share price actually lines up with its underlying value? This article walks through the numbers so you can see how the market is pricing the story. The stock closed at ¥3,578 after an 8.9% decline over the last 7 days, a 24.0% drop over 30 days and a 22.5% fall year to date, while the 1 year return sits at 83.4% and the 3 year return is very large at about 3x. These swings have come as SoftBank Group continues to be closely watched as a major...

In early March 2026, Arrcus announced a collaboration with Fujitsu and 1Finity to combine FUJITSU-MONAKA Arm-based CPUs, ArcOS software-defined networking, and high-speed optical interconnects into a secure, energy-efficient infrastructure for distributed AI workloads from edge inference to large-scale training. This partnership highlights Fujitsu’s push to align compute, networking, and optical transport for emerging Physical and enterprise AI use cases such as smart factories, robotics,...

Why Marubeni’s Branford Castle deal matters for shareholders Marubeni (TSE:8002) has drawn investor attention after committing capital to Branford Castle Partners’ new flagship fund and agreeing to work alongside the firm to source and support global investment opportunities. See our latest analysis for Marubeni. The Branford Castle agreement lands while Marubeni’s share price sits at ¥5,591, with a 1 day share price return of 4.02% and 7 day return of 3.86%. However, the 30 day share price...

OMRON (TSE:6645) has released its SF2030 2nd Stage medium term plan, outlining a broad shift toward data driven operations. The plan highlights increased focus on industrial automation, healthcare, and targeted growth in Europe. This roadmap sets out multi year priorities for redirecting investment and reshaping the company’s business mix. OMRON, trading at ¥4,532.0, enters this new phase after a mixed share price record, with a 13.4% return year to date and a 3.5% return over 1 year,...

Toro Neurovascular previously announced that the U.S. FDA had granted 510(k) clearance for its Toro 88 Superbore Catheter, with Kaneka Medical America LLC leading the U.S. commercial launch following the device’s first successful clinical use by Dr. Satoshi Tateshima. This launch underscores Kaneka’s deeper involvement in the neurovascular device market, pairing Toro’s catheter technology with Kaneka’s established U.S. sales and clinical support network. We’ll now examine how Kaneka’s role...

In March 2026, Frontier Lithium announced it had signed a non-binding Memorandum of Understanding with Panasonic Energy and Mitsubishi to explore lithium hydroxide procurement and broader collaboration around the PAK Lithium Project in Ontario, aimed at supplying North America’s electric vehicle battery supply chain from 2030. A key insight is that Mitsubishi’s existing joint venture role in the PAK Lithium Project now sits within a wider potential offtake and technical cooperation framework...